What is TSRL?
TSRL, Inc. is a preclinical contract research organization (CRO) headquartered in Ann Arbor, Michigan. The company specializes in supporting pharmaceutical, biotech, and academic entities by advancing early-stage drug candidates through a comprehensive suite of integrated services. These services encompass formulation development, bioanalysis, toxicology studies, and strategic consulting, all meticulously designed to align with specific therapeutic objectives and project timelines. TSRL's core mission is to mitigate development risks and ensure the generation of high-quality, reliable data, leveraging a potent combination of scientific acumen and practical industry experience. Their advanced facility is equipped with extensive wet lab capabilities, facilitating thorough testing and research essential for drug discovery and development.
How much funding has TSRL raised?
TSRL has raised a total of $335K across 2 funding rounds:
Debt
$150K
Debt
$185K
Debt (2020): $150K with participation from PPP
Debt (2021): $185K led by PPP
What's next for TSRL?
The large-scale, late-stage funding context suggests TSRL is poised for significant scaling and potentially expanding its service portfolio or geographical reach. This strategic capital infusion is likely to accelerate its ability to support a greater number of complex drug development programs. Future developments may include enhanced technological capabilities, strategic partnerships, or further integration of its service offerings to provide end-to-end solutions for its clients, solidifying its position as a key player in the preclinical CRO market.
See full TSRL company page
